Epidemiology of gynecologic cancers

Principles and Practice of Gynecologic Oncology: Sixth Edition

Volumn , Issue , 2013, Pages 1-29

  Brinton, Louise A ^a   Sahasrabuddhe, Vikrant V ^a   Trabert, Britton ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84974571342     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (365)

1. American Cancer Society. Cancer Facts & Figures 2012. Atlanta, GA: American Cancer Society; 2012.
2. Howlander N, Noone AM, Neyman N, et al. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
3. Parkin DM, Whelan SL, Ferlay J, et al. Cancer Incidence in Five Continents., Vol. I to VIII. Lyon, France; 2005. Report No.: IARC CancerBase No. 7.
4. Weiss NS, Szekely DR, Austin DF. Increasing incidence of endometrial cancer in the United States. N Engl J Med. 1976;294:1259-1262.
5. Brinton LA, Berman ML, Mortel R, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol. 1992;167:1317-1325.
6. Modan B, Ron E, Lerner-Geva L, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol. 1998;147:1038-1042.
7. Bernstein L, Pike MC, Ross RK, et al. Estrogen and sex hormone-binding globulin levels in nulliparous and parous women. J Natl Cancer Inst. 1985;74:741-745.
8. La Vecchia C, Franceschi S, Decarli A, et al. Risk factors for endometrial cancer at different ages. J Natl Cancer Inst. 1984;73:667-671.
9. Brinton LA, Sakoda LC, Lissowska J, et al. Reproductive risk factors for endometrial cancer among Polish women. Br J Cancer. 2007;96:1450-1456.
10. Lambe M, Wuu J, Weiderpass E, et al. Childbearing at older age and endometrial cancer risk (Sweden). Cancer Causes Control. 1999;10:43-49.
11. Dossus L, Allen N, Kaaks R, et al. Reproductive risk factors and endometrial cancer: The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2010;127:442-451.
12. Beining RM, Dennis LK, Smith EM, et al. Meta-analysis of intrauterine device use and risk of endometrial cancer. Ann Epidemiol. 2008;18:492-499.
13. Althuis MD, Moghissi KS, Westhoff CL, et al. Uterine cancer after use of clomiphene citrate to induce ovulation. Am J Epidemiol. 2005;161:607-615.
14. Calderon-Margalit R, Friedlander Y, Yanetz R, et al. Cancer risk after exposure to treatments for ovulation induction. Am J Epidemiol. 2009;169:365-375.
15. Newcomb PA, Trentham-Dietz A. Breast feeding practices in relation to endometrial cancer risk, USA. Cancer Causes Control. 2000;11:663-667.
16. MacMahon B. Risk factors for endometrial cancer. Gynecol Oncol. 1974;2:122-129.
17. Cibula D, Gompel A, Mueck AO, et al. Hormonal contraception and risk of cancer. Hum Reprod Update. 2010;16:631-650.
18. Schlesselman JJ. Cancer of the breast and reproductive tract in relation to use of oral contraceptives. Contraception. 1989;40:1-38.
19. Maxwell GL, Schildkraut JM, Calingaert B, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol. 2006;103:535-540.
20. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005;365:1543-1551.
21. Cushing KL, Weiss NS, Voigt LF, et al. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens. Obstet Gynecol. 1998;91:35-39.
22. Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv. 2004;59:368-378.
23. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA. 2003;290:1739-1748.
24. Jaakkola S, Lyytinen H, Pukkala E, et al. Endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obstet Gynecol. 2009;114:1197-1204.
25. Razavi P, Pike MC, Horn-Ross PL, et al. Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:475-483.
26. Newcomb PA, Trentham-Dietz A. Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States). Cancer Causes Control. 2003;14:195-201.
27. Allen NE, Key TJ, Dossus L, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 2008;15:485-497.
28. Trabert B, Wentzensen N, Yang HP, et al. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk?. Int J Cancer. 2012. doi: 10.1002/ijc.27623.
29. Friedenreich C, Cust A, Lahmann PH, et al. Anthropometric factors and risk of endometrial cancer: the European prospective investigation into cancer and nutrition. Cancer Causes Control. 2007;18:399-413.
30. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99:272-282.
31. Nelson HD, Fu R, Griffin JC, et al. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med. 2009;151:703-226.
32. van Leeuwen FE, Benraadt J, Coebergh JW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994;343:448-452.
33. Bland AE, Calingaert B, Secord AA, et al. Relationship between tamoxifen use and high risk endometrial cancer histologic types. Gynecol Oncol. 2009;112:150-154.
34. Schmandt RE, Iglesias DA, Co NN, et al. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am JObstet Gynecol. 2011;205:518-525.
35. Yang TY, Cairns BJ, Allen N, et al. Postmenopausal endometrial cancer risk and body size in early life and middle age: prospective cohort study. Br J Cancer. 2012;107(1):169-175.
36. Chang SC, Lacey JV Jr. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev. 2007;16:723-730.
37. Moore SC, Gierach GL, Schatzkin A, et al. Physical activity, sedentary behaviours, and the prevention of endometrial cancer. Br J Cancer. 2010;103:933-938.
38. Gierach GL, Chang SC, Brinton LA, et al. Physical activity, sedentary behavior, and endometrial cancer risk in the NIH-AARP Diet and Health Study. Int J Cancer. 2009;124:2139-2147.
39. Loerbroks A, Schouten LJ, Goldbohm RA, et al. Alcohol consumption, cigarette smoking, and endometrial cancer risk: results from the Netherlands Cohort Study. Cancer Causes Control. 2007;18:551-560.
40. Terry PD, Miller AB, Jones JG, et al. Cigarette smoking and the risk of invasive epithelial ovarian cancer in a prospective cohort study. Eur J Cancer. 2003;39:1157-1164.
41. Yang HP, Brinton LA, Platz EA, et al. Active and passive cigarette smoking and the risk of endometrial cancer in Poland. Eur J Cancer. 2010;46:690-696.
42. Polesel J, Serraino D, Zucchetto A, et al. Cigarette smoking and endometrial cancer risk: the modifying effect of obesity. Eur J Cancer Prev. 2009;18:476-481.
43. Austin H, Drews C, Partridge EE. A case-control study of endometrial cancer in relation to cigarette smoking, serum estrogen levels, and alcohol use. Am J Obstet Gynecol. 1993;169:1086-91.
44. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer. 1975;15:617-631.
45. Cui X, Rosner B, Willett WC, et al. Dietary fat, fiber, and carbohydrate intake in relation to risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:978-989.
46. Jain MG, Rohan TE, Howe GR, et al. A cohort study of nutritional factors and endometrial cancer. Eur J Epidemiol. 2000;16:899-905.
47. van LL, Kirsh VA, Kreiger N, et al. Endometrial cancer and meat consumption: a case-cohort study. Eur J Cancer Prev. 2011;20:334-339.
48. Prentice RL, Thomson CA, Caan B, et al. Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst. 2007;99:1534-1543.
49. Biel RK, Friedenreich CM, Csizmadi I, et al. Case-control study of dietary patterns and endometrial cancer risk. Nutr Cancer. 2011;63:673-686.
50. Yeh M, Moysich KB, Jayaprakash V, et al. Higher intakes of vegetables and vegetable-related nutrients are associated with lower endometrial cancer risks. J Nutr. 2009;139:317-322.
51. Uccella S, Mariani A, Wang AH, et al. Dietary and supplemental intake of one-carbon nutrients and the risk of type I and type II endometrial cancer: a prospective cohort study. Ann Oncol. 2011;22:2129-2136.
52. Kabat GC, Park Y, Hollenbeck AR, et al. Intake of fruits and vegetables, and risk of endometrial cancer in the NIH-AARP Diet and Health Study. Cancer Epidemiol. 2010;34:568-573.
53. McCullough ML, Bandera EV, Patel R, et al. A prospective study of fruits, vegetables, and risk of endometrial cancer. Am J Epidemiol. 2007;166:902-911.
54. Galeone C, Augustin LS, Filomeno M, et al. Dietary glycemic index, glycemic load, and the risk of endometrial cancer: a case-control study and meta-analysis. Eur J Cancer Prev. 2012.
55. Larsson SC, Friberg E, Wolk A. Carbohydrate intake, glycemic index and glycemic load in relation to risk of endometrial cancer: a prospective study of Swedish women. Int J Cancer. 2007;120:1103-1107.
56. Nagle CM, Olsen CM, Ibiebele TI, et al. Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis. Eur J Nutr. 2012. [Epub ahead of print].
57. Hogervorst JG, Schouten LJ, Konings EJ, et al. A prospective study of dietary acrylamide intake and the risk of endometrial, ovarian, and breast cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:2304-2313.
58. Wilson KM, Mucci LA, Rosner BA, et al. A prospective study on dietary acrylamide intake and the risk for breast, endometrial, and ovarian cancers. Cancer Epidemiol Biomarkers Prev. 2010;19:2503-2515.
59. Horn-Ross PL, John EM, Canchola AJ, et al. Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst. 2003;95:1158-1164.
60. Ollberding NJ, Lim U, Wilkens LR, et al. Legume, soy, tofu, and isoflavone intake and endometrial cancer risk in postmenopausal women in the multiethnic cohort study. J Natl Cancer Inst. 2012;104:67-76.
61. Friberg E, Orsini N, Mantzoros CS, et al. Alcohol intake and endometrial cancer risk: a meta-analysis of prospective studies. Br J Cancer. 2010;103:127-131.
62. Yang HP, Gierach GL, Danforth KN, et al. Alcohol and endometrial cancer risk in the NIH-AARP diet and health study. Int J Cancer. 2011;128:2953-2961.
63. Je Y, Giovannucci E. Coffee consumption and risk of endometrial cancer: findings from a large up-to-date meta-analysis. Int J Cancer. 2012;131:1700-1710.
64. Butler LM, Wu AH. Green and black tea in relation to gynecologic cancers. Mol Nutr Food Res. 2011;55:931-940.
65. Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod. 2012;27:1327-1331.
66. Dahlgren E, Friberg LG, Johansson S, et al. Endometrial carcinoma; ovarian dysfunction-a risk factor in young women. Eur JObstet Gynecol Reprod Biol. 1991;41:143-150.
67. Weiderpass E, Ye W, Vainio H, et al. Diabetes mellitus and ovarian cancer (Sweden). Cancer Causes Control. 2002;13:759-764.
68. Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2007;16:276-280.
69. Lindemann K, Vatten LJ, Ellstrom-Engh M, et al. Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. Br J Cancer. 2008;98:1582-1585.
70. Friedenreich CM, Biel RK, Lau DC, et al. Case-control study of the metabolic syndrome and metabolic risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2384-2395.
71. Rosato V, Zucchetto A, Bosetti C, et al. Metabolic syndrome and endometrial cancer risk. Ann Oncol. 2011;22:884-889.
72. Fortuny J, Sima C, Bayuga S, et al. Risk of endometrial cancer in relation to medical conditions and medication use. Cancer Epidemiol Biomarkers Prev. 2009;18:1448-1456.
73. Morimoto LM, Newcomb PA, Hampton JM, et al. Cholecystectomy and endometrial cancer: a marker of long-term elevated estrogen exposure? Int J Gynecol Cancer. 2006;16:1348-1353.
74. Newcomb PA, Trentham-Dietz A, Egan KM, et al. Fracture history and risk of breast and endometrial cancer. Am J Epidemiol. 2001;153:1071-1078.
75. Modugno F, Ness RB, Chen C, et al. Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiol Biomarkers Prev. 2005;14:2840-2847.
76. Bodelon C, Doherty JA, Chen C, et al. Use of nonsteroidal antiinflammatory drugs and risk of endometrial cancer. Am J Epidemiol. 2009;170:1512-1517.
77. Viswanathan AN, Feskanich D, Schernhammer ES, et al. Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res. 2008;68:2507-2513.
78. Lucenteforte E, Talamini R, Montella M, et al. Family history of cancer and the risk of endometrial cancer. Eur J Cancer Prev. 2009;18:95-99.
79. Hemminki K, Bermejo JL, Granstrom C. Endometrial cancer: population attributable risks from reproductive, familial and socioeconomic factors. Eur J Cancer. 2005;41:2155-2159.
80. Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA. 2006;296:1479-1487.
81. Gaudet MM, Yang HP, Bosquet JG, et al. No association between FTO or HHEX and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2010;19:2106-2109.
82. Lundin E, Wirgin I, Lukanova A, et al. Selected polymorphisms in sex hormone-related genes, circulating sex hormones and risk of endometrial cancer. Cancer Epidemiol. 2012;36:445-452.
83. O'Mara TA, Fahey P, Ferguson K, et al. Progesterone receptor gene variants and risk of endometrial cancer. Carcinogenesis. 2011;32:331-335.
84. O'Mara TA, Ferguson K, Fahey P, et al. CHEK2, MGMT, SULT1E1 and SULT1A1 polymorphisms and endometrial cancer risk. Twin Res Hum Genet. 2011;14:328-332.
85. Xu WH, Shrubsole MJ, Xiang YB, et al. Dietary folate intake, MTHFR genetic polymorphisms, and the risk of endometrial cancer among Chinese women. Cancer Epidemiol Biomarkers Prev. 2007;16:281-287.
86. Spurdle AB, Thompson DJ, Ahmed S, et al. Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet. 2011;43:451-454.
87. Long J, Zheng W, Xiang YB, et al. Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2012.
88. Sturgeon SR, Brock JW, Potischman N, et al. Serum concentrations of organochlorine compounds and endometrial cancer risk (United States). Cancer Causes Control. 1998;9:417-424.
89. Weiderpass E, Adami HO, Baron JA, et al. Organochlorines and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2000;9:487-493.
90. Hardell L, van BB, Lindstrom G, et al. Adipose tissue concentrations of p,p'-DDE and the risk for endometrial cancer. Gynecol Oncol. 2004;95:706-711.
91. Abel EL, Hendrix SL, McNeeley GS, et al. Use of electric blankets and association with prevalence of endometrial cancer. Eur J Cancer Prev. 2007;16:243-250.
92. McElroy JA, Newcomb PA, Trentham-Dietz A, et al. Endometrial cancer incidence in relation to electric blanket use. Am J Epidemiol. 2002;156:262-267.
93. Bernstein L, Allen M, Anton-Culver H, et al. High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control. 2002;13:625-635.
94. Weiderpass E, Pukkala E, Vasama-Neuvonen K, et al. Occupational exposures and cancers of the endometrium and cervix uteri in Finland. Am J Ind Med. 2001;39:572-580.
95. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10-17.
96. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13:295-308.
97. Arafa M, Somja J, Dehan P, et al. Current concepts in the pathology and epigenetics of endometrial carcinoma. Pathology. 2010;42:613-617.
98. Lim D, Oliva E. Nonendometrioid endometrial carcinomas. Semin Diagn Pathol. 2010;27:241-260.
99. Felix AS, Weissfeld JL, Stone RA, et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control. 2010;21:1851-1856.
100. Yang HP, Wentzensen N, Trabert B, et al. Endometrial cancer risk factors by two main histologic subtypes in the NIH-AARP Diet and Health Study. Am J Epidemiol. In press 2012.
101. Audet-Walsh E, Lepine J, Gregoire J, et al. Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics. J Clin Endocrinol Metab. 2011;96:E330-E339.
102. Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst. 1996;88:1127-1135.
103. Key TJ, Pike MC. The dose-effect relationship between "unopposed" oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer. 1988;57:205-212.
104. Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer. 2004;108:425-432.
105. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002;11:1531-1543.
106. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer. 2001;84:975-981.
107. Troisi R, Potischman N, Hoover RN, et al. Insulin and endometrial cancer. Am J Epidemiol. 1997;146:476-482.
108. Weiderpass E, Brismar K, Bellocco R, et al. Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk. Br J Cancer. 2003;89:1697-1704.
109. Siiteri PK. Steroid hormones and endometrial cancer. Cancer Res. 1978;38:4360-4366.
110. Mink PJ, Sherman ME, Devesa SS. Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978-1998. Cancer. 2002;95:2380-2389.
111. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr. Accessed December 2, 2010.
112. Greggi S, Parazzini F, Paratore MP, et al. Risk factors for ovarian cancer in central Italy. Gynecol Oncol. 2000;79:50-54.
113. Braem MG, Onland-Moret NC, van den Brandt PA, et al. Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study. Am J Epidemiol. 2010;172:1181-1189.
114. Cooper GS, Schildkraut JM, Whittemore AS, et al. Pregnancy recency and risk of ovarian cancer. Cancer Causes Control. 1999;10:397-402.
115. Negri E, Franceschi S, Tzonou A, et al. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer. 1991;49:50-56.
116. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case-control study. Br J Cancer. 1989;60:592-598.
117. Whittemore AS, Wu ML, Paffenbarger RS Jr, et al. Epithelial ovarian cancer and the ability to conceive. Cancer Res. 1989;49:4047-4052.
118. Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med. 1994;331:771-776.
119. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992;136:1184-1203.
120. Brinton LA, Sahasrabuddhe VV, Scoccia B. Fertility drugs and the risk of breast and gynecologic cancers. Semin Reprod Med. 2012;30:131-145.
121. van Leeuwen FE, Klip H, Mooij TM, et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod. 2011;26:3456-3465.
122. Chiaffarino F, Pelucchi C, Negri E, et al. Breastfeeding and the risk of epithelial ovarian cancer in an Italian population. Gynecol Oncol. 2005;98:304-308.
123. Zhang M, Xie X, Lee AH, et al. Prolonged lactation reduces ovarian cancer risk in Chinese women. Eur J Cancer Prev. 2004;13:499-502.
124. Danforth KN, Tworoger SS, Hecht JL, et al. Breastfeeding and risk of ovarian cancer in two prospective cohorts. Cancer Causes Control. 2007;18:517-523.
125. Jordan SJ, Cushing-Haugen KL, Wicklund KG, et al. Breast-feeding and risk of epithelial ovarian cancer. Cancer Causes Control. 2012;23:919-927.
126. Cibula D, Widschwendter M, Majek O, et al. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update. 2011;17:55-67.
127. Rice MS, Murphy MA, Tworoger SS. Tubal ligation, hysterectomy and ovarian cancer: a meta-analysis. J Ovarian Res. 2012;5:13.
128. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91:1459-1467.
129. Chiaffarino F, Pelucchi C, Parazzini F, et al. Reproductive and hormonal factors and ovarian cancer. Ann Oncol. 2001;12:337-341.
130. Tsilidis KK, Allen NE, Key TJ, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer. 2011;105:1436-1442.
131. Schildkraut JM, Bastos E, Berchuck A. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst. 1997;89:932-938.
132. Franceschi S, La Vecchia C, Booth M, et al. Age at menarche and at menopause. Int J Cancer. 1991;49:57-60.
133. Beral V, Doll R, Hermon C, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371:303-314.
134. Lurie G, Thompson P, McDuffie KE, et al. Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Obstet Gynecol. 2007;109:597-607.
135. Ness RB, Grisso JA, Klapper J, et al. SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol. 2000;152:233-241.
136. Schildkraut JM, Calingaert B, Marchbanks PA, et al. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst. 2002;94:32-38.
137. Greer JB, Modugno F, Allen GO, et al. Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer.. Obstet Gynecol. 2005;105:731-740.
138. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95:s1-s66.
139. Pearce CL, Chung K, Pike MC, et al. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer. 2009;115:531-539.
140. Morch LS, Lokkegaard E, Andreasen AH, et al. Hormone therapy and ovarian cancer. JAMA. 2009;302:298-305.
141. Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA. 1995;274:1926-1930.
142. Rinaldi S, Dossus L, Lukanova A, et al. Endogenous androgens and risk of epithelial ovarian cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiol Biomarkers Prev. 2007;16:23-29.
143. Lukanova A, Lundin E, Akhmedkhanov A, et al. Circulating levels of sex steroid hormones and risk of ovarian cancer. Int J Cancer. 2003;104:636-642.
144. Tworoger SS, Lee IM, Buring JE, et al. Plasma androgen concentrations and risk of incident ovarian cancer. Am J Epidemiol. 2008;167:211-218.
145. McSorley MA, Alberg AJ, Allen DS, et al. Prediagnostic circulating follicle stimulating hormone concentrations and ovarian cancer risk. Int J Cancer. 2009;125:674-679.
146. Lukanova A, Lundin E, Micheli A, et al. Risk of ovarian cancer in relation to prediagnostic levels of C-peptide, insulin-like growth factor binding proteins-1 and -2 (USA, Sweden, Italy). Cancer Causes Control. 2003;14:285-292.
147. Parazzini F, Moroni S, La Vecchia C, et al. Ovarian cancer risk and history of selected medical conditions linked with female hormones. Eur J Cancer. 1997;33:1634-1637.
148. Brinton LA, Gridley G, Persson I, et al. Am J Obstet Gynecol. 1997;176:572-579.
149. Brinton LA, Sakoda LC, Sherman ME, et al. Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. Cancer Epidemiol Biomarkers Prev. 2005;14:2929-2935.
150. Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol. 2002;155:217-224.
151. Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13:385-394.
152. Ness RB. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol. 2003;189:280-294.
153. Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 1995;4:447-451.
154. Lin HW, Tu YY, Lin SY, et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol. 2011;12:900-904.
155. Harlow BL, Cramer DW, Baron JA, et al. Psychotropic medication use and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 1998;7:697-702.
156. Dalton SO, Johansen C, Mellemkjaer L, et al. Antidepressant medications and risk for cancer. Epidemiology. 2000;11:171-176.
157. Dublin S, Rossing MA, Heckbert SR, et al. Risk of epithelial ovarian cancer in relation to use of antidepressants, benzodiazepines, and other centrally acting medications. Cancer Causes Control. 2002;13:35-45.
158. Kato I, Zeleniuch-Jacquotte A, Toniolo PG, et al. Psychotropic medication use and risk of hormone-related cancers: the New York University Women's Health Study. J Public Health Med. 2000;22:155-160.
159. Lacey JV Jr, Sherman ME, Hartge P, et al. Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer. 2004;108:281-286.
160. Cramer DW, Harlow BL, Titus-Ernstoff L, et al. Over-the-counter analgesics and risk of ovarian cancer. Lancet. 1998;351:104-107.
161. Rodriguez C, Henley SJ, Calle EE, et al. Paracetamol and risk of ovarian cancer mortality in a prospective study of women in the USA. Lancet. 1998;352:1354-1355.
162. Schildkraut JM, Moorman PG, Halabi S, et al. Analgesic drug use and risk of ovarian cancer. Epidemiology. 2006;17:104-107.
163. Bonovas S, Filioussi K, Sitaras NM. Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol. 2005;60:194-203.
164. Olsen CM, Green AC, Whiteman DC, et al. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer. 2007;43:690-709.
165. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLOS Med. 2012;94:e1001200.
166. Schouten LJ, Rivera C, Hunter DJ, et al. Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev. 2008;17:902-912.
167. Lahmann PH, Cust AE, Friedenreich CM, et al. Anthropometric measures and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010;126:2404-2415.
168. Greer JB, Modugno F, Ness RB, et al. Anthropometry and the risk of epithelial ovarian cancer. Cancer. 2006;106:2247-2257.
169. Leitzmann MF, Koebnick C, Danforth KN, et al. Body mass index and risk of ovarian cancer. Cancer. 2009;115:812-822.
170. Purdie DM, Bain CJ, Webb PM, et al. Body size and ovarian cancer: case-control study and systematic review (Australia). Cancer Causes Control. 2001;12:855-863.
171. Yang HP, Trabert B, Murphy MA, et al. Ovarian cancer risk factors by histologic subtypes in the NIH-AARP diet and health study. Int J Cancer. 2011;131(4):938-948.
172. Gram IT, Lukanova A, Brill I, et al. Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study. Int J Cancer. 2012;130:2204-2210.
173. Jordan SJ, Whiteman DC, Purdie DM, et al. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol. 2006;103:1122-1129.
174. Baker JA, Odunuga OO, Rodabaugh KJ, et al. Active and passive smoking and risk of ovarian cancer. Int J Gynecol Cancer. 2006;16(suppl 1):211-218.
175. Goodman MT, Tung KH. Active and passive tobacco smoking and the risk of borderline and invasive ovarian cancer (United States). Cancer Causes Control. 2003;14:569-577.
176. Cramer DW, Harlow BL, Willett WC, et al. Galactose consumption and metabolism in relation to the risk of ovarian cancer. Lancet. 1989;2:66-71.
177. Bosetti C, Negri E, Franceschi S, et al. Diet and ovarian cancer risk: a case-control study in Italy. Int J Cancer. 2001;93:911-915.
178. Goodman MT, Wu AH, Tung KH, et al. Association of dairy products, lactose, and calcium with the risk of ovarian cancer. Am J Epidemiol. 2002;156:148-157.
179. Kushi LH, Mink PJ, Folsom AR, et al. Prospective study of diet and ovarian cancer. Am J Epidemiol. 1999;149:21-31.
180. Larsson SC, Bergkvist L, Wolk A. Milk and lactose intakes and ovarian cancer risk in the Swedish Mammography Cohort. Am J Clin Nutr. 2004;80:1353-1357.
181. Fairfield KM, Hunter DJ, Colditz GA, et al. A prospective study of dietary lactose and ovarian cancer. Int J Cancer. 2004;110:271-277.
182. Genkinger JM, Hunter DJ, Spiegelman D, et al. A pooled analysis of 12 cohort studies of dietary fat, cholesterol and egg intake and ovarian cancer. Cancer Causes Control. 2006;17:273-285.
183. Wallin A, Orsini N, Wolk A. Red and processed meat consumption and risk of ovarian cancer: a dose-response meta-analysis of prospective studies. Br J Cancer. 2011;104:1196-1201.
184. Kolahdooz F, van der Pols JC, Bain CJ, et al. Meat, fish, and ovarian cancer risk: results from 2 Australian case-control studies, a systematic review, and meta-analysis. Am J Clin Nutr. 2010;91:1752-1763.
185. Larsson SC, Holmberg L, Wolk A. Fruit and vegetable consumption in relation to ovarian cancer incidence: the Swedish Mammography Cohort. Br J Cancer. 2004;90:2167-2170.
186. McCann SE, Freudenheim JL, Marshall JR, et al. Risk of human ovarian cancer is related to dietary intake of selected nutrients, phytochemicals and food groups. J Nutr. 2003;133:1937-1942.
187. Pelucchi C, La Vecchia C, Chatenoud L, et al. Dietary fibres and ovarian cancer risk. Eur J Cancer. 2001;37:2235-2239.
188. Koushik A, Hunter DJ, Spiegelman D, et al. Fruits and vegetables and ovarian cancer risk in a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev. 2005;14:2160-2167.
189. Pan SY, Ugnat AM, Mao Y, et al. A case-control study of diet and the risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:1521-1527.
190. Tung KH, Wilkens LR, Wu AH, et al. Association of dietary vitamin A, carotenoids, and other antioxidants with the risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:669-676.
191. Harris HR, Cramer DW, Vitonis AF, et al. Folate, vitamin B6, vitamin B12, methionine and alcohol intake in relation to ovarian cancer risk. Int J Cancer. 2011;131:E518-E529.
192. Navarro Silvera SA, Jain M, Howe GR, et al. Dietary folate consumption and risk of ovarian cancer: a prospective cohort study. Eur J Cancer Prev. 2006;15:511-515.
193. Cook LS, Neilson HK, Lorenzetti DL, et al. A systematic literature review of vitamin D and ovarian cancer. Am JObstet Gynecol. 2010;203:70-78.
194. Genkinger JM, Hunter DJ, Spiegelman D, et al. Alcohol intake and ovarian cancer risk: a pooled analysis of 10 cohort studies. Br J Cancer. 2006;94:757-762.
195. Lueth NA, Anderson KE, Harnack LJ, et al. Coffee and caffeine intake and the risk of ovarian cancer: the Iowa Women's Health Study. Cancer Causes Control. 2008;19:1365-1372.
196. Kuper H, Titus-Ernstoff L, Harlow BL, et al. Population based study of coffee, alcohol and tobacco use and risk of ovarian cancer. Int J Cancer. 2000;88:313-318.
197. Riman T, Dickman PW, Nilsson S, et al. Some life-style factors and the risk of invasive epithelial ovarian cancer in Swedish women. Eur J Epidemiol. 2004;19:1011-1019.
198. Jordan SJ, Purdie DM, Green AC, et al. Coffee, tea and caffeine and risk of epithelial ovarian cancer. Cancer Causes Control. 2004;15:359-365.
199. Oppeneer SJ, Robien K. Tea consumption and epithelial ovarian cancer risk: a systematic review of observational studies. Nutr Cancer. 2011;63:817-826.
200. Tworoger SS, Gertig DM, Gates MA, et al. Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer. 2008;112:1169-1177.
201. Pharoah PD, Ponder BA. The genetics of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2002;16:449-468.
202. Hemminki K, Granstrom C. Familial invasive and borderline ovarian tumors by proband status, age and histology. Int J Cancer. 2003;105:701-705.
203. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108:171-182.
204. Hartge P, Whittemore AS, Itnyre J, et al. The Collaborative Ovarian Cancer Group.. Obstet Gynecol. 1994;84:760-764.
205. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med. 2003;348:2339-2347.
206. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008;359:2143-2153.
207. Gayther SA, Pharoah PD. The inherited genetics of ovarian and endometrial cancer. Curr. Opin Genet Dev. 2010;20:231-238.
208. Mills PK, Riordan DG, Cress RD, et al. Perineal talc exposure and epithelial ovarian cancer risk in the Central Valley of California. Int J Cancer. 2004;112:458-464.
209. Wu AH, Pearce CL, Tseng CC, et al. Markers of inflammation and risk of ovarian cancer in Los Angeles County. Int J Cancer. 2009;124:1409-1415.
210. Boffetta P, Andersen A, Lynge E, et al. Employment as hairdresser and risk of ovarian cancer and non-Hodgkin's lymphomas among women. J Occup Med. 1994;36:61-65.
211. Donna A, Crosignani P, Robutti F, et al. Triazine herbicides and ovarian epithelial neoplasms.. Scand J Work Environ Health. 1989;15:47-53.
212. Vasama-Neuvonen K, Pukkala E, Paakkulainen H, et al. Ovarian cancer and occupational exposures in Finland.. Am J Ind Med. 1999;36:83-89.
213. Langseth H, Kjaerheim K. Ovarian cancer and occupational exposure among pulp and paper employees in Norway. Scand J Work Environ Health. 2004;30:356-361.
214. Shields T, Gridley G, Moradi T, et al. Occupational exposures and the risk of ovarian cancer in Sweden. Am J Ind Med. 2002;42:200-213.
215. Macarthur AC, Le ND, Abanto ZU, et al. Occupational female breast and reproductive cancer mortality in British Columbia, Canada, 1950-94. Occup Med (Lond). 2007;57:246-253.
216. Sala M, Dosemeci M, Zahm SH. A death certificate-based study of occupation and mortality from reproductive cancers among women in 24 US states. J Occup Environ Med. 1998;40:632-639.
217. Camargo MC, Stayner LT, Straif K, et al. Occupational exposure to asbestos and ovarian cancer: a meta-analysis. Environ Health Perspect. 2011;119:1211-1217.
218. Shen N, Weiderpass E, Antilla A, et al. Epidemiology of occupational and environmental risk factors related to ovarian cancer. Scand J Work Environ Health. 1998;24:175-182.
219. Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol. 2009;472:413-437.
220. Kurman RJ, Shih I. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol. 2011;42:918-931.
221. Modugno F, Ness RB, Wheeler JE. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. Ann Epidemiol. 2001;11:568-574.
222. Risch HA, Marrett LD, Jain M, et al. Results of a case-control study. Am J Epidemiol. 1996;144:363-372.
223. Gates MA, Rosner BA, Hecht JL, et al. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol. 2010;171:45-53.
224. Franceschi S, La Vecchia C, Helmrich SP, et al. Risk factors for epithelial ovarian cancer in Italy. Am J Epidemiol. 1982;115:714-719.
225. Purdie DM, Bain CJ, Siskind V, et al. Ovulation and risk of epithelial ovarian cancer. Int J Cancer. 2003;104:228-232.
226. Moorman PG, Schildkraut JM, Calingaert B, et al. Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). Cancer Causes Control. 2002;13:807-811.
227. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 1998;90:1774-1786.
228. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst. 1983;71:717-721.
229. Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia? Lancet. 1971;2:163.
230. Zajicek J. Ovarian cystomas and ovulation, a histogenetic concept. Tumori. 1977;63:429-435.
231. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol. 2009;10:321-322.
232. Schiffman M, Wentzensen N, Wacholder S, et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103:368-383.
233. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
234. Arbyn M, Castellsague X, de Sanjose S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22:2675-2686.
235. Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLOS Med. 2008;5:e132.
236. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907.
237. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
238. National Cancer Institute. SEER Cancer Statistics Review. 1975-2008. 2012.
239. Horner MJ, Altekruse SF, Zou Z, et al. U.S. geographic distribution of prevaccine era cervical cancer screening, incidence, stage, and mortality. Cancer Epidemiology, Biomarkers & Prevention. 2011;20:591-599.
240. Chan PG, Sung HY, Sawaya GF. Changes in cervical cancer incidence after three decades of screening US women less than 30 years old. Obstet Gynecol. 2003;102:765-773.
241. Reimers LL, Anderson WF, Rosenberg PS, et al. Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-period-cohort models. Cancer Epidemiol Biomarkers Prev. 2009;18:792-800.
242. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
243. Liebrich C, Brummer O, Von Wasielewski R, et al. Primary cervical cancer truly negative for high-risk human papillomavirus is a rare but distinct entity that can affect virgins and young adolescents. Eur J Gynaecol Oncol. 2009;30:45-48.
244. Plummer M, Schiffman M, Castle PE, et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195:1582-1589.
245. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis. 2005;191:1808-1816.
246. Koshiol J, Lindsay L, Pimenta JM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008;168:123-137.
247. Wentzensen N, Walker J, Schiffman M, et al. Heterogeneity of high grade cervical intraepithelial neoplasia related to HPV16: implications for natural history and management. Int J Cancer. 2013;132:148-154.
248. Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128:927-935.
249. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121.
250. Wheeler CM, Hunt WC, Joste NE, et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst. 2009;101:475-487.
251. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048-1056.
252. Cornet I, Gheit T, Franceschi S, et al. HPV16 genetic variants: phylogeny and classification based on E6 and LCR. J Virol. 2012;86:6855-6861.
253. Ramanakumar AV, Goncalves O, Richardson H, et al. Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women. BMC Infect Dis. 2010;10:326.
254. Gravitt PE, Kovacic MB, Herrero R, et al. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer. 2007;121:2787-2793.
255. Chen HC, Schiffman M, Lin CY, et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst. 2011;103:1387-1396.
256. Schiffman M, Rodriguez AC, Chen Z, et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res. 2010;70:3159-3169.
257. Schiffman M, Glass AG, Wentzensen N, et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev 2011;20:1398-1409.
258. Castle PE, Fetterman B, Thomas Cox J, et al. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. Obstet Gynecol. 2010;116;76-81.
259. Sahasrabuddhe VV, Luhn P, Wentzensen N. Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiol. 2011;6:1083-1098.
260. Castle PE, Schiffman M, Wheeler CM, et al. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113:18-25.
261. Wang SS, Bratti MC, Rodriguez AC, et al. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis. 2009;199:20-30.
262. Einstein MH, Schiller JT, Viscidi RP, et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis. 2009;9:347-356.
263. Einstein MH. Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines. Cancer Immunol Immunother 2008;57:443-451.
264. Ferguson M, Wilkinson DE, Heath A, et al. The first international standard for antibodies to HPV 16. Vaccine. 2011;29:6520-6526.
265. Gravitt PE. The known unknowns of HPV natural history. J Clin Invest. 2011;121:4593-4599.
266. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9:425-434.
267. Shepherd JP, Frampton GK, Harris P. Interventions for encouraging sexual behaviours intended to prevent cervical cancer. Cochrane Database Syst Rev. 2011;4:CD001035.
268. Plummer M, Peto J, Franceschi S. Time since first sexual intercourse and the risk of cervical cancer. Int J Cancer. 2012;130:2638-2644.
269. Monroy OL, Aguilar C, Lizano M, et al. Prevalence of human papillomavirus genotypes, and mucosal IgA anti-viral responses in women with cervical ectopy. J Clin Virol.:47:43-48.
270. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006;354:2645-2654.
271. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis. 2002;29:725-735.
272. Burchell AN, Tellier PP, Hanley J, et al. Influence of partner's infection status on prevalent human papillomavirus among persons with a new sex partner. Sex Transm Dis. 2010;37:34-40.
273. Castellsague X, Bosch FX, Munoz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med. 2002;346:1105-1112.
274. Auvert B, Sobngwi-Tambekou J, Cutler E, et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis. 2009;199:14-19.
275. Wawer MJ, Tobian AA, Kigozi G, et al. Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. Lancet. 2011;377:209-218.
276. Munoz N, Franceschi S, Bosetti C, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet. 2002;359:1093-1101.
277. Hildesheim A, Wang SS. Host and viral genetics and risk of cervical cancer: a review. Virus Res. 2002;89:229-240.
278. Appleby P, Beral V, Berrington de Gonzalez A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370:1609-1621.
279. de Villiers EM. Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. Int J Cancer. 2003;103:705-708.
280. Harris TG, Miller L, Kulasingam SL, et al. Depot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection. Am J Obst Gynecol. 2009;200489.e1-e8.
281. Castellsague X, Diaz M, Vaccarella S, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol. 2011;12:1023-1031.
282. Roberts JN, Kines RC, Katki HA, et al. Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. J Natl Cancer Inst. 2011;103:737-743.
283. Parikh S, Brennan P, Boffetta P. Meta-analysis of social inequality and the risk of cervical cancer. Int J Cancer. 2003;105:687-691.
284. Louie KS, Castellsague X, de Sanjose S, et al. Smoking and passive smoking in cervical cancer risk: pooled analysis of couples from the IARC multicentric case-control studies. Cancer Epidemiol Biomarkers Prev. 2011;207:1379-1390.
285. Kapeu AS, Luostarinen T, Jellum E, et al. Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. Am J Epidemiol. 2009;169:480-488.
286. Hellberg D, Stendahl U. The biological role of smoking, oral contraceptive use and endogenous sexual steroid hormones in invasive squamous epithelial cervical cancer. Anticancer Res. 2005;25:3041-3046.
287. Pratt MM, Sirajuddin P, Poirier MC, et al. Polycyclic aromatic hydrocarbon-DNA adducts in cervix of women infected with carcinogenic human papillomavirus types: an immunohistochemistry study. Mutation Res. 2007;624:114-123.
288. Siegel EM, Patel N, Lu B, et al. Biomarkers of oxidant load and type-specific clearance of prevalent oncogenic human papillomavirus infection: markers of immune response?. Int J Cancer. 2012;131:219-228.
289. Nowak RG, Gravitt PE, Morrison CS, et al. Increases in human papillomavirus detection during early HIV infection among women in Zimbabwe. J Infect Dis. 2011;203:1182-1191.
290. Cohen CR, Moscicki AB, Scott ME, et al. Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa. AIDS. 2010;24.
291. de Araujo Souza PS, Sichero L, Maciag PC. HPV variants and HLA polymorphisms: the role of variability on the risk of cervical cancer. Future Oncol. 2009;5:359-370.
292. Vink JM, van Kemenade FJ, Meijer CJ, et al. Cervix smear abnormalities: linking pathology data in female twins, their mothers and sisters. Eur J Hum Genet. 2011;19:108-111.
293. Engelmark MT, Ivansson EL, Magnusson JJ, et al. Polymorphisms in 9q32 and TSCOT are linked to cervical cancer in affected sib-pairs with high mean age at diagnosis. Hum Genet. 2008;123:437-443.
294. Myung SK, Ju W, Kim SC, et al. Vitamin or antioxidant intake (or serum level) and risk of cervical neoplasm: a meta-analysis. BJOG: Int J Obs Gynaecol. 2011;118:1285-1291.
295. Madeleine MM, Anttila T, Schwartz SM, et al. Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer. 2007;120:650-655.
296. Bratcher LF, Sahasrabuddhe VV. The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research. Infect Agent Cancer. 2010;5:8.
297. Chaturvedi AK, Madeleine MM, Biggar RJ, et al. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst. 2009;101:1120-1130.
298. Walker F, Adle-Biassette H, Madelenat P, et al. Increased apoptosis in cervical intraepithelial neoplasia associated with HIV infection: implication of oncogenic human papillomavirus, caspases, and Langerhans cells. Clin Cancer Res: Official J Am Assoc Cancer Res 2005;11:2451-2458.
299. Shrestha S, Wang C, Aissani B, et al. Interleukin-10 gene (IL10) polymorphisms and human papillomavirus clearance among immunosupressed adolescents. Cancer Epidemiol Biomarkers Prev. 2007;16:1626-1632.
300. Behbahani H, Walther-Jallow L, Klareskog E, et al. Proinflammatory and type 1 cytokine expression in cervical mucosa during HIV-1 and human papillomavirus infection. J Acquir Immune Defic Syndr. 2007;45:9-19.
301. Syrjanen S. Human papillomavirus infection and its association with HIV. Adv Dent Res. 2011;23:84-89.
302. Seoud M, Tjalma WA, Ronsse V. Cervical adenocarcinoma: moving towards better prevention. Vaccine. 2011;29:9148-9158.
303. Clifford G, Franceschi S. Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix. Int J Cancer. 2008;122;1684-1685.
304. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-2119.
305. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120:885-891.
306. Lacey JV, Jr., Swansonca, Brinton LA, et al. Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer. 2003;98:814-821.
307. Jaakkola S, Pukkala E, K. Postmenopausal estradiol-progestagen therapy and risk for uterine cervical cancer. Int J Cancer. 2011;131: E537-E543.
308. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147-172.
309. Saraiya M, Watson M, Wu X, et al. Incidence of in situ and invasive vulvar cancer in the US, 1998-2003. Cancer. 2008;113(10Suppl): 2865-2872.
310. van der Avoort IA, Shirango H, Hoevenaars BM, et al. Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways. Int J Gynecol Pathol. 2006;25:22-29.
311. Eva LJ, Ganesan R, Chan KK, et al. Vulval squamous cell carcinoma occurring on a background of differentiated vulval intraepithelial neoplasia is more likely to recur: a review of 154 cases. J Reprod Med. 2008;53:397-401.
312. van Seters M, ten Kate FJ, van Beurden M, et al. In the absence of (early) invasive carcinoma, vulvar intraepithelial neoplasia associated with lichen sclerosus is mainly of undifferentiated type: new insights in histology and aetiology. J clinic pathol. 2007;60:504-509.
313. Judson PL, Habermann EB, Baxter NN, et al. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol. 2006;107:1018-1022.
314. Beckmann AM, Kiviat NB, Daling JR, et al. Human papillomavirus type 16 in multifocal neoplasia of the female genital tract. Int J Gynecol Pathol. 1988;7:39-47.
315. Garland SM, Insinga RP, Sings HL, et al. Human papillomavirus infections and vulvar disease development. Cancer Epidemiol Biomarkers Prev. 2009;18:1777-1784.
316. De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124:1626-1636.
317. Madsen BS, Jensen HL, van den Brule AJ, et al. Risk factors for invasive squamous cell carcinoma of the vulva and vagina-population-based case-control study in Denmark. Int J Cancer. 2008;122:2827-2834.
318. Hussain SK, Madeleine MM, Johnson LG, et al. Cervical and vulvar cancer risk in relation to the joint effects of cigarette smoking and genetic variation in interleukin 2. Cancer Epidemiol Biomarkers Prev. 2008;177:1790-1799.
319. Brinton LA, Nasca PC, Mallin K, et al. Case-control study of cancer of the vulva. Obstet Gynecol. 1990;75:859-866.
320. Nordenvall C, Chang ET, Adami HO, et al. Cancer risk among patients with condylomata acuminata. Int J Cancer. 2006;119:888-893.
321. Massad LS, Xie X, Darragh T, et al. Genital warts and vulvar intraepithelial neoplasia: natural history and effects of treatment and human immunodeficiency virus infection. Obstet Gynecol. 2011;118:831-839.
322. Hussain SK, Sundquist J, Hemminki K. Familial clustering of cancer at human papillomavirus-associated sites according to the Swedish Family-Cancer Database. Int J Cancer. 2008;122:1873-1878.
323. Santegoets LA, van Seters M, Heijmans-Antonissen C, et al. Reduced local immunity in HPV-related VIN: expression of chemokines and involvement of immunocompetent cells. Int J Cancer. 2008;123:616-622.
324. Lilic V, Lilic G, Filipovic S, et al. Primary carcinoma of the vagina. J BUON. 2010;15:241-247.
325. Hoover RN, Hyer M, Pfeiffer RM, et al. Adverse health outcomes in women exposed in utero to diethylstilbestrol. N Engl J Med. 2011;365:1304-1314.
326. Brinton LA, Reeves WC, Brenes MM, et al. Oral contraceptive use and risk of invasive cervical cancer. Int J Epidemiol. 1990;19:4-11.
327. Sherman JF, Mount SL, Evans MF, et al. Smoking increases the risk of high-grade vaginal intraepithelial neoplasia in women with oncogenic human papillomavirus. Gynecol Oncol. 2008;110:396-401.
328. Balamurugan A, Ahmed F, Saraiya M, et al. Potential role of human papillomavirus in the development of subsequent primary in situ and invasive cancers among cervical cancer survivors. Cancer. 2008;113(10Suppl):2986-2945.
329. Madkan VK, Cook-Norris RH, Steadman MC, et al. The oncogenic potential of human papillomaviruses: a review on the role of host genetics and environmental cofactors. Br J Dermatol. 2007;157:228-241.
330. Srodon M, Stoler MH, Baber GB, et al. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol. 2006;30:1513-1518.
331. Smith EK, White MC, Weir HK, et al. Higher incidence of clear cell adenocarcinoma of the cervix and vagina among women born between 1947 and 1971 in the United States. Cancer Causes Control. 2012;23:207-211.
332. Herbst AL, Anderson S, Hubby MM, et al. Risk factors for the development of diethylstilbestrol-associated clear cell adenocarcinoma: a case-control study. Am J Obstet Gynecol. 1986;154:814-822.
333. Troisi R, Hatch EE, Titus-Ernstoff L, et al. Cancer risk in women prenatally exposed to diethylstilbestrol. Int J Cancer. 2007;121:356-360.
334. Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 2010;203:531-539.
335. Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376:717-729.
336. Smith HO, Qualls CR, Prairie BA, et al. Trends in gestational choriocarcinoma: a 27-year perspective. Obstet Gynecol. 2003;102:978-987.
337. Bracken MB, Brinton LA, Hayashi K. Epidemiology of hydatidiform mole and choriocarcinoma. Epidemiol Rev. 1984;6:52-75.
338. Steigrad SJ. Epidemiology of gestational trophoblastic diseases. Best Pract Res Clin Obstet Gynaecol. 2003;17:837-847.
339. Tham BW, Everard JE, Tidy JA, et al. Gestational trophoblastic disease in the Asian population of Northern England and North Wales. BJOG: Int J Obs Gynaeco. 2003;110:555-559.
340. Brinton LA, Bracken MB, Connelly RR. Choriocarcinoma incidence in the United States. Am J Epidemiol. 1986;123:1094-1100.
341. Smith HO, Hilgers RD, Bedrick EJ, et al. Ethnic differences at risk for gestational trophoblastic disease in New Mexico: a 25-year population-based study. Am J Obstet Gynecol. 2003;188:357-366.
342. Lybol C, Thomas CM, Bulten J, et al. Increase in the incidence of gestational trophoblastic disease in the Netherlands. Gynecol Oncol. 2011;121:334-338.
343. Salehi S, Eloranta S, Johansson AL, et al. Reporting and incidence trends of hydatidiform mole in Sweden 1973-2004. Acta Oncol. 2011;50:367-372.
344. Garrett LA, Garner EI, Feltmate CM, et al. Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia. Journal Reprod Med. 2008;53:481-486.
345. Altieri A, Franceschi S, Ferlay J, et al. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol. 2003;4:670-678.
346. Tuncer ZS, Bernstein MR, Wang J, et al. Repetitive hydatidiform mole with different male partners. Gynecol Oncol. 1999;75:224-226.
347. Wang SS, Trunk M, Schiffman M, et al. Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica. Cancer Epidemiol Biomarkers Prev. 2004;13:1355-1360.
348. Bagshawe KD, Rawlins G, Pike MC, et al. ABO blood-groups in trophoblastic neoplasia. Lancet. 1971;1:553-556.
349. Dawood MY, Teoh ES, Ratnam SS. ABO blood group in trophoblastic disease. J Obstet Gynaecol Br Commonw. 1971;78:918-923.
350. Messerli ML, Lilienfeld AM, Parmley T, et al. Risk factors for gestational trophoblastic neoplasia. Am J Obstet Gynecol. 1985;153:294-300.
351. Parazzini F, La Vecchia C, Franceschi S, et al. ABO blood-groups and the risk of gestational trophoblastic disease. Tumori. 1985;71:123-126.
352. Brinton LA, Wu BZ, Wang W, et al. Gestatioal trophoblasic disease: a case-contorl study from the People's Republic of China. Am J Obstet Gynecol. 1989;161:121-127.
353. Parazzini F, La Vecchia C, Pampallona S, et al. Reproductive patterns and the risk of gestational trophoblastic disease. Am J Obstet Gynecol. 1985;152:866-870.
354. Kashanian M, Baradaran HR, Teimoori N. Risk factors for complete molar pregnancy: a study in Iran. J Reprod Med. 2009;54:621-624.
355. La Vecchia C, Franceschi S, Parazzini F, et al. Risk factors for gestational trophoblastic disease in Italy. Am J Epidemiol. 1985;121:457-464.
356. Buckley JD, Henderson BE, Morrow CP, et al. Case-control study of gestational choriocarcinoma. Cancer Res. 1988;48:1004-1010.
357. Berkowitz RS, Cramer DW, Bernstein MR, et al. Risk factors for complete molar pregnancy from a case-control study. Am J Obstet Gynecol. 1985;152:1016-1020.
358. Palmer JR, Driscoll SG, Rosenberg L, et al. Oral contraceptive use and risk of gestational trophoblastic tumors. J Natl Cancer Inst. 1999;91:635-640.
359. Parazzini F, Cipriani S, Mangili G, et al. Oral contraceptives and risk of gestational trophoblastic disease. Contraception. 2002;65:425-427.
360. Ho YB, Burch P. Relationship of oral contraceptives and the intrauterine contraceptive devices to the regression of concentrations of the beta subunit of human chorionic gonadotropin and invasive complications after molar pregnancy. Am J Obstet Gynecol. 1983;145:214-217.
361. Stone M, Dent J, Kardana A, et al. Relationship of oral contraception to development of trophoblastic tumour after evacuation of a hydatidiform mole. Br J Obstet Gynaecol. 1976;83:913-916.
362. Curry SL, Schlaerth JB, Kohorn EI, et al. Hormonal contraception and trophoblastic sequelae after hydatidiform mole (a Gynecologic Oncology Group Study). Am J Obstet Gynecol. 1989;160:805-809.
363. Morrow P, Nakamura R, Schlaerth J, et al. The influence of oral contraceptives on the postmolar human chorionic gonadotropin regression curve. Am J Obstet Gynecol. 1985;151:906-914.
364. La Vecchia C, Parazzini F, Decarli A, et al. Age of parents and risk of gestational trophoblastic disease. J Natl Cancer Inst. 1984;73:639-642.
365. Hoffner L, Surti U. The genetics of gestational trophoblastic disease: a rare complication of pregnancy. Cancer Genet. 2012;205:63-77.